ライフサイエンスコーパス: renal function

1 for the 5-mg dose in patients with preserved renal function.

2 P<0.001) compared with patients with normal renal function.

3 mogranin A level, baseline blood counts, and renal function.

4 tal admission for heart failure, or impaired renal function.

5 illed cysts and progressive deterioration of renal function.

6 as a sensitive marker in detecting impaired renal function.

7 t, and fluid retention as well as to improve renal function.

8 aled an increased dysregulation with loss of renal function.

9 ent of diabetes, and development of impaired renal function.

10 ad a 60% survival with recovery of liver and renal function.

11 eoxy guanosine levels, and also deteriorated renal function.

12 was associated with the degree of worsening renal function.

13 onin (hs-cTn) concentrations irrespective of renal function.

14 rtend poor outcomes independently of age and renal function.

15 immune biomarkers and markers of hepatic and renal function.

16 with the overall population for efficacy and renal function.

17 n and 30- and 180-day mortality according to renal function.

18 that is cleared by the kidney and linked to renal function.

19 P<0.001) compared with patients with normal renal function.

20 and independently associated with worsening renal function.

21 tion, left ventricular ejection fraction, or renal function.

22 score variables, coronary heart disease, and renal function.

23 thotrexate and capecitabine for pretreatment renal function.

24 especially in patients with initially normal renal function.

25 w risk, and better correlated with follow-up renal function.

26 din PGE2, a secreted autacoid that maintains renal function.

27 hich ameliorates MV rarefaction and improves renal function.

28 emia, though none had rapid deterioration of renal function.

29 hm for CF-LVAD candidates with poor baseline renal function.

30 barrier, leading to proteinuria and reduced renal function.

31 ce less than 90 mL/min predicted declines in renal function.

32 n over time and also in those with worsening renal function.

33 several microRNAs correlated with indexes of renal function.

34 ned whether this association was modified by renal function.

35 etabolic abnormalities, can adversely affect renal function.

36 al fibrosis, which in turn, leads to loss of renal function.

37 a suitable PET tracer for quantification of renal function.

38 in patients with normal, poor, and worsening renal function.

39 colistin in patients with various degrees of renal function.

40 pid (<2 wk) and progressive deterioration of renal function.

41 gulation and injury, urinary biomarkers, and renal function.

42 ion, apoptosis, cyst formation, and impaired renal function.

43 and led to improved bone mineral density and renal function.

44 of viral or other initial liver disease, or renal function.

45 out ADPKD that was matched for age, sex, and renal function.

46 to systemic hemodynamics, inflammation, and renal function.

47 's immune cells, without adversely affecting renal function.

48 of ELA and Apelin-13 on vascular and cardio-renal function.

49 h) for 7-14 days; regimens were adjusted for renal function.

50 status 0-2, and adequate haematological and renal function.

51 tion is also associated with preservation of renal function.

52 iated with serum levels of IS independent of renal function.

53 e accessibility, with improvement in overall renal function.

54 progressive decline in renal blood flow and renal function.

55 ated patients with normal or mildly impaired renal function.

56 points included hyperkalemia and changes in renal function.

57 o under basal conditions without a change in renal function.

58 (2), and compared it to patients with normal renal function.

59 neous retaining the remaining parenchyma and renal function.

60 deficiency of RIPK3 or MLKL did not preserve renal function.

61 nkephalins that is correlated inversely with renal function.

62 nd aldolase levels and thyroid, hepatic, and renal function.

63 eated with (131)I previously or had abnormal renal function.

64 0-1, and adequate bone marrow, hepatic, and renal function.

65 lar effects in non-diabetic rats with normal renal functions.

66 e event), with few adverse events related to renal function (1% vs <1%) or volume depletion (<1% vs 0

67 er incidence of vascular death versus stable renal function (2.21 versus 1.41 events per 100 patient-

68 tion or cardiac death than those with normal renal function (24% versus 10%; adjusted hazard ratio, 2

69 reduced interstitial fibrosis, and superior renal function 30 days after ischemia/reperfusion injury

70 s with RD compared with patients with normal renal function (31% versus 13%, P<0.001).

71 italized (73 vs 81, P = .039), and decreased renal function (42% vs 19%, P = .008) by 3 months after

72 to Assess Treatment Effect on Congestion and Renal Function), a trial comparing the effects of rolofy

73 late matter (PM2.5) is associated with lower renal function, a cardiovascular risk factor.

74 ayed groups, respectively, failed to recover renal function (absolute difference, -34.8%; 95% CI, -54

75 We evaluated associations between CI and renal function across multiple subgroups and assessed fo

76 ciations were observed between CI and better renal function across multiple subgroups defined by indi

77 transplantation is associated with improved renal function after 1 year but increases the risk of ac

78 tho-overexpressing mice had better preserved renal function after AKI.

79 nvestigation as a more meaningful measure of renal function after critical illness.

80 us left ventricular assist device (pLVAD) on renal function after high-risk PCI remains unknown.

81 al NAD and less fat accumulation with better renal function after ischaemia.

82 th, chronic dialysis, or a permanent loss of renal function after the primary discharge.

83 ld or older are likely to recover sufficient renal function allowing renal replacement therapy discon

84 An impaired renal function also leads to 1,25-vitamin D3 deficiency

85 39), including 17 patients with compromised renal function and 22 patients with known (n = 16) or su

86 stitial fibrosis, and significantly improved renal function and animal survival.

87 afe in hypertensive subjects who have normal renal function and are receiving ACEi and/or ARB therapy

88 r-1), an inhibitor of ferroptosis, preserved renal function and decreased histologic injury, oxidativ

89 pital, skin biopsies and close monitoring of renal function and drug concentrations occurred weekly f

90 assess the relationship between pretreatment renal function and five end points: toxicity, dose modif

91 research to explain the association between renal function and GCC thickness.

92 the time of the biopsy associated with worse renal function and higher proteinuria but did not correl

93 Renal function and histologic morphology were evaluated.

94 in acute HF and are prognostic for worsening renal function and in-hospital mortality as well as mort

95 long-term PM2.5 exposure negatively affects renal function and increases renal function decline.

96 itical for maintaining the CD epithelium and renal function and is a key intermediate for periostin a

97 idney cysts that ultimately leads to loss of renal function and kidney failure.

98 nephritis, which was accompanied by a better renal function and less renal damage.

99 5 mg twice daily) in patients with preserved renal function and might be a reasonable alternative to

100 n before are receiving diagnoses of impaired renal function and nephrosclerosis-age-associated histol

101 coid receptor (GR) knockout mice had similar renal function and protein excretion compared to wild ty

102 ith myocardial infarction were stratified by renal function and randomized 1:1:1 to CSL112 (2 g apoA-

103 reotide pretreatment significantly preserved renal function and reduced the severity of renal injury.

104 expression of periostin displayed preserved renal function and structure during GN.

105 sigma1-receptor agonist, improved survival, renal function and structure, and the inflammatory respo

106 the expression of RTN1A correlates with the renal function and the severity of kidney injury in pati

107 L-11 were strongly protected against loss of renal function and tubule injury due to reduced compleme

108 relationship between cystatin C (a marker of renal function) and PASP and potential mediators, includ

109 approach delivers fundamental parameters of renal function, and because of its ease of use and speed

110 zations, renal biopsies, rejection episodes, renal function, and blood concentration of medications.

111 MP3 is required for normal NKCC2 expression, renal function, and blood pressure.

112 s subgroups based on glycaemia, insulin use, renal function, and cardiovascular disease status.

113 nts included symptom improvement, changes in renal function, and clinical events.

114 her baseline blood pressure, better baseline renal function, and fewer comorbidities.

115 s index, medications, lesion characteristic, renal function, and high-sensitivity C-reactive protein,

116 n 1.1, adequate haematological, hepatic, and renal function, and immune-competent status (patients wi

117 t failure, electrocardiographical variables, renal function, and other comorbidities.

118 a major cardiac event than those with normal renal function, and should be considered for further inv

119 tcomes including patient and graft survival, renal function, and technical complications.

120 the effect of RDN on mean arterial pressure, renal function, and the reflex response to hemorrhage in

121 n persistent Epo synthesis despite declining renal function, and this maintenance may result in part

122 es the effects of rifaximin on hemodynamics, renal function, and vasoactive hormones.

123 long-term survival, regardless of underlying renal function, and was accompanied by low rates of adve

124 (TAVR) and the effect of TAVR on subsequent renal function are, to our knowledge, unknown.

125 cular disease and 72 individuals with normal renal function as the control group.

126 In two mouse models of CKD, the decline in renal function associated with the accumulation of IS in

127 ion (OR, 0.95; 95% CI, 0.76-1.19; P = 0.63), renal function at 1 year (coefficient, 0.97; 95% CI, 0.9

128 converted to mTORi had significantly better renal function at 1 year after randomization compared wi

129 using FTIR imaging by comparing results with renal function at 3 months after transplantation (M3) an

130 eraged hematuria, time-averaged proteinuria, renal function at baseline, and the presence of tubuloin

131 composite of graft loss or no improvement in renal function at day 12.

132 e patients is often mild and does not impact renal function at day 30, while infection/ sepsis is the

133 antification by FTIR imaging correlated with renal function at M3, and the variation in fibrosis betw

134 sphamide pulses (15 mg/kg adapted to age and renal function) at 3-week intervals, PPH (6x), and high-

135 east 55%; adequate bone marrow, hepatic, and renal function; at least one measureable lesion; and kno

136 Statements are grouped into 4 areas: (A) renal function; (B) time of EVR introduction, CNI reduct

137 ast episode of AKI, despite return to normal renal function before pregnancy, associated with adverse

138 er transplantation (M3) and the variation of renal function between M3 and M12.

139 Despite a higher rate of worsening renal function, blood pressure reduction was not associa

140 cal tests in both blood and urine related to renal functions, blood pressure values.

141 es medication history, serum glucose, HbA1c, renal function, BMI, and blood pressure.

142 In conclusion, CEPO improves renal function, body and kidney weight, and survival in

143 h rate of mortality and the deterioration of renal function (both log-rank tests, P <0.0001).

144 DN reduced blood pressure and improved basal renal function but markedly compromised compensatory hem

145 inases increased post-SNx peaking at loss of renal function but TG2 was the predominant enzyme.

146 MP numbers decreased with declining renal function, but no clear association with disease ac

147 te of death, dialysis, or sustained impaired renal function by day 30 after surgery did not differ be

148 of NAFLD elevated fetuin-A levels may impair renal function by RSF-induced proinflammatory signalling

149 luences of the female hormone cycle on basic renal functions by studying excretion of urinary marker

150 ects included changes in plasma aldosterone, renal function, cardiac variables, and electrolytes.

151 events (death, dialysis, and durable loss of renal function [chronic kidney disease]).

152 rmin use was lower among patients with lower renal function classes.

153 cantly increased survival rates and improved renal function compared with similarly treated WT, Mer-K

154 Improvement in renal function, compared with baseline values, occurred

155 re, patient characteristics, such as age and renal function, confound the association between NOAC dr

156 Renal function criteria should enable liberal creatinine

157 involved in phagocytosis, and prevented the renal function decline and injury induced in mice by a t

158 occurred in 46% of the patients, the rate of renal function decline changed from -6.45+/-14.66 to -0.

159 agliflozin decreases albuminuria and reduces renal function decline independently of its glycemic eff

160 Renal function decline is common among patients with AF

161 atively affects renal function and increases renal function decline.

162 a potential therapeutic target to attenuate renal function decline.

163 y the study end, both monotherapies improved renal function, decreasing glomerular hyperfiltration an

164 ion within 1 year, and in-hospital worsening renal function, defined as a rise in plasma creatinine >

165 morphisms studied had a noticeable impact on renal function degradation at 10 years.

166 ear regression analyses of 6-month recipient renal function demonstrated that higher urinary NGAL and

167 During the study period, renal function deteriorated in 135 (25.3%) patients and

168 tial case of a 56-year-old woman with normal renal function developing unexplained ARF without hypovo

169 oside had no influence on follow-up PFT, and renal function did not influence PFT.

170 Renal function did not significantly affect sensitivity

171 Renal function did not worsen on LDV/SOF regimens with T

172 mast cells prior to IRI resulted in improved renal function due to diminished local inflammatory cyto

173 cant associations between PTDM and change in renal function during the first 5 years or acute rejecti

174 nts were more likely to experience worsening renal function during treatment.

175 When participants were stratified by renal function (eGFR < vs. >/=90 mL/min/1.73 m(2)), TMAO

176 2); n=722) to 57%-61% with severely impaired renal function (eGFR<30 ml/min per 1.73 m(2); n=81) and

177 atients in the contrast group had borderline renal function (estimated glomerular filtration rate <45

178 progression to ESRD), changes in cardiac and renal function, Fabry-related symptoms (pain, hypohidros

179 udy, the effects of serelaxin on cardiac and renal function, fibrosis, inflammation and lipid accumul

180 predictive values decreased with decreasing renal function from 51%-57% with normal function to 27%-

181 Specificity decreased with impaired renal function from 93%-95% with normal function (eGFR>/

182 e associated with NS play conserved roles in renal function from flies to humans.

183 Renal function generally is assessed by measurement of G

184 costeroids to patients with rather preserved renal function (GFR>50 ml/min per 1.73 m(2)) and persist

185 5 mg BID in patients with normal or impaired renal function (glomerular filtration rate >80 mL/min or

186 Even in healthy individuals, renal function gradually declines during aging.

187 Thus, the renal function has been considered.

188 AN induced AKI, indicated by the analysis of renal function, histology, and apoptosis.

189 ality were higher in patients with worsening renal function (HR, 1.53; 95% CI, 1.17-2.01 for stroke o

190 genes were enriched in processes crucial for renal function, identifying dysregulated geranylgeranyl

191 lmonary perfusion quantification; and in (d) renal function imaging, where blood velocities and glome

192 rom patients with renal TILs correlated with renal function impairment.

193 Cockcroft-Gault estimated renal function improved over time, which may be attribut

194 er pro-ENK levels predict CKD and decline of renal function in a prospective cohort of 2568 participa

195 ut bolus) enhanced decongestion or preserved renal function in AHF patients with renal dysfunction.

196 No acute rejections, no differences in renal function in all individuals, and no differences in

197 vels of sCD40L and sCD40R predict changes in renal function in an all-cause chronic kidney disease (C

198 7 that have not previously been analysed for renal function in an animal model.

199 eover, it restored fitness, fur density, and renal function in both fast aging Xpd(TTD/TTD) and natur

200 mplete reversal of hypertension and improved renal function in CKD-RDN sheep (p < 0.0001 for 2 and 5

201 ontinuous pressure-controlled NEVKP improves renal function in DCD kidney transplantation.

202 rmation that improves the ability to predict renal function in donors.

203 ) proteins, was previously found to preserve renal function in experimental polycystic kidney disease

204 (16 mg/day) and unexplained deterioration in renal function in follow-up (patients were tapered from

205 the effect of intravenous contrast media on renal function in neonates.

206 ized that the hepatokine fetuin-A may impair renal function in non alcoholic fatty liver disease (NAF

207 kade also decreases proteinuria and protects renal function in non-transplant patients with chronic k

208 osure to ambient fine particulate matter and renal function in older men: the VA Normative Aging Stud

209 d routine monitoring of serum potassium, and renal function in patients treated with a mineralocortic

210 0L and sCD40R are associated with changes in renal function in patients with CKD.

211 h, interstitial fibrosis, and the decline in renal function in PKD mice.

212 oves local NAD levels, fat accumulation, and renal function in post-ischaemic Pgc1alpha(-/-) mice.

213 Fourteen glycan traits were associated with renal function in the discovery sample (P<6.5x10(-4)) an

214 with the perfusion parameters (P = 0.649) or renal function in the donor (R = 0.02458: P = 0.271).

215 ciated with increased mortality and impaired renal function in the first postoperative year.

216 ally meaningful trend for improved long-term renal function in the SRL/MMF group compared with the CN

217 nts in the IASD group and 1 event (worsening renal function) in the control group (P=1.0).

218 n apical receptor with key developmental and renal functions, in MDCK cells.

219 itch to agalsidase-alpha showed a decline of renal function independent of the eGFR formula used.

220 ge of time of last ingestion of the NOAC and renal function is critical to managing these patients gi

221 Although chronic deterioration in renal function is frequently seen after cardiac transpla

222 ng fibrin thrombi is less than 50% and donor renal function is preserved.

223 sfunction is solely attributable to impaired renal function is unclear.

224 advanced glycation end products (AGEs) with renal function loss (RFL) and its structural determinant

225 e and more effective than placebo in slowing renal function loss in patients with diabetic nephropath

226 microbial metabolism, although the effect of renal function loss per se in humans may be inferior to

227 tients requiring RRT had significantly worse renal function, lower hemoglobin, and increased proteinu

228 iltration rates to patients' vital signs and renal function may be associated with more effective dec

229 IC patients, monitoring and preserving their renal function may be beneficial as well.

230 We analyzed the correlation between renal function measured as eGFR and 76 N-glycan traits u

231 sease (CVD), independent of creatinine-based renal function measurements.

232 ve uncovered genomic regions associated with renal function metrics and risk of CKD.

233 nts from Europe and rest of world (eg, worse renal function, more diabetes, older age).

234 Critically ill patients with stable renal function (n = 307) who received intravascular cont

235 orsened eGFR (>/=10% lower), or no change in renal function (neither).

236 ction was strongly associated with worsening renal function (odds ratio, 1.9; 95% confidence interval

237 PENK independently predicted worsening renal function (odds ratio: 1.58; 95% confidence interva

238 However, the renal function of the hCD55 mice was not preserved in th

239 ssed the effects of proteinuria and baseline renal function on long-term renal and survival outcomes

240 uximab therapy did not significantly improve renal function or proteinuria assessed over 1 year.

241 ime of index biopsy, serum creatinine levels/renal function over 24 months of follow-up, and graft fa

242 llent patient and graft survival, and stable renal function over 4 years.

243 nd M12 correlated well with the variation in renal function over the same period.

244 e consistent in patients with normal or poor renal function over time and also in those with worsenin

245 is that elamipretide plus PTRA would improve renal function, oxygenation, and RBF in patients with at

246 P < .001), diabetes (P < .001), and impaired renal function (P < .001); and had higher N-terminal pro

247 centration was mainly associated with better renal function (P<0.05).

248 one mineral density, vascular calcification, renal function, patient and graft survival, and economic

249 y (PTRA) and stenting often fails to recover renal function, possibly because of ischemia/reperfusion

250 Postoperatively, his renal function precluded adjuvant cisplatin-based chemot

251 to Assess Treatment Effect on Congestion and Renal Function (PROTECT) trial and validated in 1776 pat

252 Dasatinib treatment also improved renal function, reduced albuminuria, and inhibited expre

253 therapy increased the risk of deteriorating renal function, regardless of baseline estimated glomeru

254 l evidence of organ dysfunction, recovery of renal function, requirement of RRT after day 90, duratio

255 nt animals, thereby preserving and restoring renal function, respectively.

256 with empagliflozin decreases with declining renal function, resulting in less potency for glucose lo

257 Routine biochemistry (full blood count and renal function) results were normal.

258 CNI withdrawal after HTx on albuminuria and renal function seem dissociated; hence, the clinical sig

259 mia, and analyzed 24 h after reperfusion for renal function (serum creatinine and urea), complement d

260 with clinically normal renal function, thus renal function should be closely monitored in these pati

261 out acute kidney injury, where ICU discharge renal function should reflect ongoing baseline, discharg

262 were analyzed according to kidney diseases, renal function (staging according to CKD-epidemiology co

263 alpha, interleukins, hemogram, and liver and renal function tests were performed at days 0 and 5.

264 pe (higher affinity variant) exhibited worse renal function than carriers of the lower affinity varia

265 The magnitude of decline in renal function that should be tolerated during intensive

266 and is associated with significantly better renal function, that is, no nephrotoxicity.

267 In people with normal renal function, the annual incidence of chronic kidney d

268 Among ICU patients with stable renal function, the benefit of using sodium bicarbonate

269 val compared to those with clinically normal renal function, thus renal function should be closely mo

270 patient and graft survivals with comparable renal function to open technique.

271 tion in hypertensive individuals with normal renal function treated with an ACEi or ARB.

272 Renal function trends were estimated using a repeated-me

273 ) and paired baseline and 30-day measures of renal function undergoing TAVR in the PARTNER 1 trial an

274 The rate of decline of renal function varies significantly among individuals wi

275 agonists improved postischemic survival and renal function via activation of Akt-mediated nitric oxi

276 n was associated with greater improvement in renal function vs albumin alone in patients with cirrhos

277 Renal function was also similar at 6, 12, and 36 months.

278 After 21 days, renal function was assessed, and tissue was collected to

279 Worsening renal function was associated with a higher risk of subs

280 Worsening of renal function was defined as an annual decrease in esti

281 Relative renal function was determined after a low activity (62.9

282 Impaired renal function was determined via urinary albumin/creati

283 patients with atrial fibrillation, declining renal function was more common in elderly patients and t

284 ts, outcomes, donor-specific antibodies, and renal function was performed, as were renal biopsies.

285 patients reaching ESRD or a 50% reduction of renal function was significantly greater among patients

286 morbid conditions, clinical risk scores, and renal function were analyzed in patients with or without

287 on (APACHE) II score, severity of sepsis and renal function were enrolled.

288 ol, 10 treatment) with DSA and deteriorating renal function were enrolled.

289 Measures of renal function were obtained in inpatient neonates who u

290 ntricular assist device patients with stable renal function were planned for this prospective, random

291 try, blood gases, cytokines, and cardiac and renal function were recorded.

292 Histological injury and renal function were similar but the study was not powere

293 Measures of renal function were the major determinants of PENK level

294 of Ascites criteria of rapidly deteriorating renal function) were assigned randomly to groups given i

295 t renal tubular cells significantly improved renal function when administered intravenously 24 and 48

296 s) that was not seen in patients with stable renal function who were randomized to receive rivaroxaba

297 nem 500 mg every 8 hours (doses adjusted for renal function), with possible oral antibiotic switch af

298 Worsening renal function (WRF) often occurs during acute heart fai

299 utcomes differ among patients with worsening renal function (WRF) taking these new drugs compared wit

300 irrespective of the occurrence of worsening renal function (WRF).